Trial Profile
Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed ovarian cancer (2nd or further line)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms T-RACE II; TRACE-II
- 18 Jul 2019 Status changed from suspended to discontinued.
- 09 Aug 2018 Status changed to suspended at the moment
- 22 May 2014 New trial record